Antibiotics provide no benefit for patients with idiopathic pulmonary fibrosis, study finds
Doctors have hoped that antibiotics could benefit patients with chronic lung diseases, but a new study has found no benefit for patients with life-threatening idiopathic pulmonary fibrosis in preventing hospitalization or death.
While there were no statistical benefits for patients with the lung-scarring disease, the new research will prevent unnecessary antibiotic use that could contribute to the growing problem of antibiotic resistance. The nationwide clinical trial - believed to be the largest idiopathic pulmonary fibrosis trial ever conducted - also collected biological samples that will advance the understanding and treatment of the mysterious and ultimately fatal illness.
May 19, 2021
Adding antibiotics to usual care does not improve outcomes for people with the lung disease idiopathic pulmonary fibrosis (IPF), according to the findings from a multi-center, phase 3 clinical trial sponsored by Weill Cornell Medicine.
Importantly, the investigators note that although the trial had negative findings, the novel way it was designed and conducted could pave the way for future studies that are less expensive and easier to conduct. The research was published May 11 in JAMA: The Journal of the American Medical Association.
“IPF is a rare but fatal disorder that has a prognosis worse than most cancers and, unfortunately, has very limited therapeutic options,” said lead author Dr. Fernando J. Martinez, the Bruce Webster Professor of Internal Medicine at Weill Cornell Medicine and chief of pulmonary and critical care medicine at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center. “There has been a lot of interest in trying to de
Beyond the mouse model: Yale project advances treatments for lung disease yale.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yale.edu Daily Mail and Mail on Sunday newspapers.
The Schools of Medicine at Yale and University of Pittsburgh are joining forces with Three Lakes Foundation to accelerate a cure for pulmonary fibrosis
News provided by
Share this article
Share this article
CHICAGO, March 17, 2021 /PRNewswire/ Three Lakes Foundation (TLF) has announced that it has selected Yale University School of Medicine and the University of Pittsburgh School of Medicine to join the
Three Lakes Consortium for Pulmonary Fibrosis (TLC4PF). Together, they will focus on advancing disease understanding with the goal to accelerate new treatments and curing this devastating lung condition.
Naftali Kaminski, MD, Yale School of Medicine and Melanie Königshoff, MD, University of Pittsburgh School of Medicine are joining forces with Three Lakes Foundation
Pitt Researchers Receive Grant to Study Long-Term Lung Disease - UPMC & Pitt Health Sciences News Blog upmc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from upmc.com Daily Mail and Mail on Sunday newspapers.